Karyopharm Therapeutics Inc. (KPTI) shareholders
Close on Nov 9, 2026Market cap $1.16KP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Peter Kolchinsky Joint filing with RA Capital Management, L.P. (9.90%), Rajeev Shah (9.90%) and 1 more | 2,302,504 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Rajeev Shah Joint filing with RA Capital Management, L.P. (9.90%), Peter Kolchinsky (9.90%) and 1 more | 2,078,913 | 9.90% | 13G (passive) | Mar 26, 2026 |
| Affinity Asset Advisors, LLC Joint filing with Michael Cho (8.60%) | 2,073,517 | 8.60% | 13G (passive) amendment | Mar 31, 2026 |
| Commodore Capital Master LP Joint filing with Commodore Capital LP (9.90%), Robert Egen Atkinson (9.90%) and 1 more | 1,950,000 | 9.90% | 13G (passive) | Mar 26, 2026 |
| Michael Cho Joint filing with Affinity Asset Advisors, LLC (8.60%) | 1,713,092 | 8.60% | 13G (passive) amendment | Jan 22, 2026 |
| Opaleye Management Inc. Joint filing with Opaleye, L.P. (9.48%), James Silverman (9.48%) | 1,569,002 | 9.48% | 13G (passive) | Oct 10, 2025 |
| T. Rowe Price Investment Management, Inc. | 1,539,147 | 6.60% | 13G (passive) amendment | May 31, 2026 |
| Robert Atchinson Joint filing with Adage Capital Management, L.P. (6.78%), Phillip Gross (6.78%) | 1,536,736 | 6.78% | 13G (passive) amendment | Jun 30, 2026 |
| Israel A. Englander Joint filing with Integrated Core Strategies (US) LLC (5.70%), Millennium Management LLC (5.70%) and 1 more | 1,297,297 | 5.70% | 13G (passive) | Aug 31, 2026 |
| BlackRock, Inc. | 1,266,084 | 5.60% | 13G (passive) | Jun 30, 2026 |
| Affinity Healthcare Fund, LP Joint filing with Affinity Asset Advisors, LLC (7.83%) | 664,224 | 7.83% | 13G (passive) | Apr 3, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of KPTI | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 1,917,354 | – | $18.73M | – | 0.16% |
| Adage Capital Partners Gp, L.L.C. | 1,521,322 | – | $14.86M | −285,000 | 0.02% |
| Acorn Capital Advisors, LLC | 1,518,113 | – | $14.83M | +1,230,287 | 4.05% |
| Goldman Sachs Group Inc | 1,424,658 | – | $13.92M | +477,079 | 0.00% |
| BlackRock, Inc. | 1,418,799 | – | $13.86M | +1,173,900 | 0.00% |
| Kalehua Capital Management LLC | 1,371,288 | – | $13.40M | New | 4.27% |
| Vanguard Capital Management LLC | 958,979 | – | $9.37M | +219,234 | 0.00% |
| Catalio Capital Management, LP | 940,855 | – | $9.19M | +43,146 | 1.73% |
| Avidity Partners Management LP | 924,487 | – | $9.03M | −2,995 | 1.45% |
| T. Rowe Price Investment Management, Inc. | 786,309 | – | $7.68M | −755,781 | 0.01% |
| Two Sigma Investments, LP | 695,264 | – | $6.79M | +544,032 | 0.00% |
| NEA Management Company, LLC | 576,780 | – | $5.64M | New | 0.35% |
| Geode Capital Management, LLC | 531,231 | – | $5.19M | +325,098 | 0.00% |
| Ghisallo Capital Management LLC | 500,000 | – | $4.89M | New | 0.10% |
| Soleus Capital Management, L.P. | 440,000 | – | $4.30M | – | 0.15% |
| UBS Group AG | 353,545 | – | $3.45M | +159,528 | 0.00% |
| State Street Corp | 325,991 | – | $3.18M | +245,249 | 0.00% |
| Affinity Asset Advisors, LLC | 312,500 | – | $3.05M | −187,500 | 0.14% |
| Brevan Howard Capital Management LP | 309,817 | – | $3.03M | +97,450 | 0.02% |
| Millennium Management LLC | 305,676 | – | $2.99M | −114,895 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 96 | 22M | 34 / 30 | 14 / 14 | 9M | 5M |
| Q1 2026 | 76 | 18M | 24 / 31 | 10 / 15 | 12M | 3M |
| Q4 2025 | 69 | 10M | 27 / 19 | 5 / 9 | 7M | 0M |
| Q3 2025 | 51 | 3M | 7 / 7 | 20 / 5 | 0M | 2M |
| Q2 2025 | 49 | 4M | 12 / 12 | 6 / 10 | 1M | 0M |
| Q1 2025 | 47 | 3M | 47 / 0 | 0 / 0 | 3M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
66 funds held KPTI in Q2 2026, 65% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of KPTI | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 677,729 | – | $6.62M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 490,317 | – | $4.79M | 0.01% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 435,070 | – | $4.25M | 0.04% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 263,084 | – | $2.57M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 216,009 | – | $414.74K | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 153,539 | – | $1.50M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 94,581 | – | $860.69K | 0.00% | May 31, 2026 |
| iShares Russell 2000 Growth ETF | 81,441 | – | $795.68K | 0.01% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 66,938 | – | $653.98K | 0.04% | Jun 30, 2026 |
| Ultra-Small Company Fund | 49,873 | – | $487.26K | 0.49% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 48,520 | – | $93.16K | 0.00% | Jul 31, 2026 |
| Master Small Cap Index Series | 37,232 | – | $363.76K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 34,152 | – | $310.78K | 0.00% | May 31, 2026 |
| Nomura Healthcare Fund | 33,333 | – | $325.66K | 0.04% | Jun 30, 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 32,185 | – | $61.80K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Richard A. Paulson | President and CEO, Director | 269,747 | May 15, 2026 |
| Kristin Abate | Chief Accounting Officer | 18,616 | Oct 19, 2026 |
| Stuart Poulton | EVP, Chief Development Officer | 94,632 | Jul 30, 2026 |
| Reshma Rangwala | EVP & Chief Medical Officer | 56,829 | May 15, 2026 |
| Sohanya Roshan Cheng | EVP & Chief Commercial Officer | 107,940 | May 15, 2026 |
| Michael Mano | EVP, CLO&Secretary | 94,398 | May 15, 2026 |
| Lori Macomber | EVP, CFO & Treasurer | 85,105 | Feb 4, 2026 |
| Christy J. Oliger | Director | 15,508 | May 26, 2026 |
| Chen Schor | Director | 15,508 | May 26, 2026 |
| Barry E. Greene | Director | 16,415 | May 26, 2026 |
| Garen G. Bohlin | Director | 18,517 | May 26, 2026 |
| Deepika Pakianathan | Director | 15,508 | May 26, 2026 |
| Zhen Su | Director | 15,508 | May 26, 2026 |
| Mansoor Raza Mirza | Director | 17,121 | May 29, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kristin Abate Chief Accounting Officer | Oct 16, 2026 | Sale | −4,788 | $0.34 | $1.65K | 18,616 |
| Kristin Abate Chief Accounting Officer | Oct 1, 2026 | Sale | −378 | $1.19 | $450 | 23,404 |
| Kristin Abate Chief Accounting Officer | Sep 1, 2026 | Sale | −19 | $2.02 | $38 | 23,782 |
| Stuart Poulton EVP, Chief Development Officer | Jul 28, 2026 | Sale | −189 | $7.10 | $1.34K | 94,632 |
| Christy J. Oliger Director | May 21, 2026 | Award | +15,508 | – | – | 15,508 |
| Garen G. Bohlin Director | May 21, 2026 | Award | +15,508 | – | – | 18,517 |
| Zhen Su Director | May 21, 2026 | Award | +15,508 | – | – | 15,508 |
| Chen Schor Director | May 21, 2026 | Award | +15,508 | – | – | 15,508 |
| Deepika Pakianathan Director | May 21, 2026 | Award | +15,508 | – | – | 15,508 |
| Barry E. Greene Director | May 21, 2026 | Award | +15,508 | – | – | 16,415 |
| Stuart Poulton EVP, Chief Development Officer | May 14, 2026 | Sale | −403 | $9.50 | $3.83K | 94,821 |
| Kristin Abate Chief Accounting Officer | May 14, 2026 | Sale | −53 | $9.50 | $504 | 23,801 |
| Michael Mano EVP, CLO&Secretary | May 14, 2026 | Sale | −266 | $9.50 | $2.53K | 94,398 |
| Richard A. Paulson President and CEO, Director | May 14, 2026 | Sale | −2,203 | $9.50 | $20.93K | 269,747 |
| Reshma Rangwala EVP & Chief Medical Officer | May 14, 2026 | Sale | −408 | $9.50 | $3.88K | 56,829 |
| Sohanya Roshan Cheng EVP & Chief Commercial Officer | May 14, 2026 | Sale | −324 | $9.50 | $3.08K | 107,940 |
| Stuart Poulton EVP, Chief Development Officer | May 13, 2026 | Award | +896 | – | – | 95,224 |
| Kristin Abate Chief Accounting Officer | May 13, 2026 | Award | +121 | – | – | 23,854 |
| Michael Mano EVP, CLO&Secretary | May 13, 2026 | Award | +700 | – | – | 94,664 |
| Richard A. Paulson President and CEO, Director | May 13, 2026 | Award | +4,920 | – | – | 271,950 |
| Reshma Rangwala EVP & Chief Medical Officer | May 13, 2026 | Award | +947 | – | – | 57,237 |
| Sohanya Roshan Cheng EVP & Chief Commercial Officer | May 13, 2026 | Award | +947 | – | – | 108,264 |
| Reshma Rangwala EVP & Chief Medical Officer | Apr 21, 2026 | Sale | −449 | $8.94 | $4.01K | 56,290 |
| Stuart Poulton EVP, Chief Development Officer | Mar 2, 2026 | Sale | −5,101 | $9.41 | $48.00K | 94,328 |
| Kristin Abate Chief Accounting Officer | Mar 2, 2026 | Sale | −559 | $9.41 | $5.26K | 22,063 |
| Michael Mano EVP, CLO&Secretary | Mar 2, 2026 | Sale | −3,526 | $9.41 | $33.18K | 93,964 |
| Richard A. Paulson President and CEO, Director | Mar 2, 2026 | Sale | −12,361 | $9.41 | $116.32K | 267,030 |
| Sohanya Roshan Cheng EVP & Chief Commercial Officer | Mar 2, 2026 | Sale | −4,604 | $9.41 | $43.32K | 107,317 |
| Reshma Rangwala EVP & Chief Medical Officer | Mar 2, 2026 | Sale | −5,066 | $9.41 | $47.67K | 56,739 |
| Stuart Poulton EVP, Chief Development Officer | Feb 17, 2026 | Sale | −378 | $8.63 | $3.26K | 99,429 |
| Richard A. Paulson President and CEO, Director | Feb 5, 2026 | Award | +81,060 | – | – | 279,391 |
| Lori Macomber EVP, CFO & Treasurer | Feb 3, 2026 | Sale | −1,626 | $6.30 | $10.24K | 85,105 |
| Lori Macomber EVP, CFO & Treasurer | Jan 31, 2026 | Award | +32,415 | – | – | 86,731 |
| Sohanya Roshan Cheng EVP & Chief Commercial Officer | Jan 31, 2026 | Award | +32,415 | – | – | 111,921 |
| Michael Mano EVP, CLO&Secretary | Jan 31, 2026 | Award | +32,415 | – | – | 97,490 |
| Stuart Poulton EVP, Chief Development Officer | Jan 31, 2026 | Award | +32,415 | – | – | 99,807 |
| Reshma Rangwala EVP & Chief Medical Officer | Jan 31, 2026 | Award | +32,415 | – | – | 61,805 |
| Kristin Abate Chief Accounting Officer | Jan 28, 2026 | Sale | −50 | $7.03 | $352 | 22,622 |
| Kristin Abate Chief Accounting Officer | Jan 27, 2026 | Award | +92 | – | – | 22,672 |
| Kristin Abate Chief Accounting Officer | Jan 21, 2026 | Sale | −265 | $5.96 | $1.58K | 22,580 |
| Richard A. Paulson President and CEO, Director | Oct 15, 2025 | Award | +114,285 | – | – | 198,331 |
| Michael Mano SVP, General Counsel&Secretary | Oct 15, 2025 | Award | +43,650 | – | – | 65,075 |
| Lori Macomber EVP, CFO & Treasurer | Oct 15, 2025 | Award | +43,650 | – | – | 54,316 |
| Kristin Abate Chief Accounting Officer | Oct 15, 2025 | Award | +12,799 | – | – | 22,845 |
| Stuart Poulton EVP, Chief Development Officer | Oct 15, 2025 | Award | +39,682 | – | – | 67,392 |
| Sohanya Roshan Cheng EVP & Chief Commercial Officer | Oct 15, 2025 | Award | +43,650 | – | – | 79,506 |
| Kristin Abate Chief Accounting Officer | Oct 1, 2025 | Sale | −362 | $6.30 | $2.28K | 10,046 |
| Sohanya Roshan Cheng EVP & Chief Commercial Officer | Sep 15, 2025 | Sale | −325 | $6.43 | $2.09K | 35,856 |
| Richard A. Paulson President and CEO, Director | Sep 15, 2025 | Sale | −1,257 | $6.43 | $8.08K | 84,046 |
| Michael Mano SVP, General Counsel&Secretary | Sep 15, 2025 | Sale | −234 | $6.43 | $1.50K | 21,425 |
| Kristin Abate Chief Accounting Officer | Sep 15, 2025 | Sale | −23 | $6.43 | $148 | 10,408 |
| Stuart Poulton EVP, Chief Development Officer | Sep 15, 2025 | Sale | −401 | $6.43 | $2.58K | 27,710 |
| Reshma Rangwala EVP & Chief Medical Officer | Sep 15, 2025 | Sale | −408 | $6.43 | $2.62K | 29,390 |
| Sohanya Roshan Cheng EVP & Chief Commercial Officer | Sep 12, 2025 | Award | +945 | – | – | 36,181 |
| Richard A. Paulson President and CEO, Director | Sep 12, 2025 | Award | +2,800 | – | – | 85,303 |
| Michael Mano SVP, General Counsel&Secretary | Sep 12, 2025 | Award | +612 | – | – | 21,659 |
| Kristin Abate Chief Accounting Officer | Sep 12, 2025 | Award | +46 | – | – | 10,431 |
| Stuart Poulton EVP, Chief Development Officer | Sep 12, 2025 | Award | +888 | – | – | 28,111 |
| Reshma Rangwala EVP & Chief Medical Officer | Sep 12, 2025 | Award | +945 | – | – | 29,798 |
| Kristin Abate Chief Accounting Officer | Sep 3, 2025 | Sale | −12 | $6.78 | $81 | 9,463 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Karyopharm Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 144,292 shares on Sep 3, 2026 over the last 90 days.
See a number that looks wrong?